BofA: Investors pour into bonds, pull back from crypto
LEXINGTON, MA—Toby Ferguson, the Chief Medical (TASE:BLWV) Officer at Voyager Therapeutics, Inc. (NASDAQ:VYGR), recently sold a portion of his company stock. The transaction comes as the company’s shares trade near their 52-week low of $3.10, down about 56% over the past six months. According to a filing with the Securities and Exchange Commission, Ferguson sold 10,086 shares of common stock on April 2, 2025. The shares were sold at an average price of $3.43, resulting in a total transaction value of $34,594. InvestingPro analysis suggests the stock is currently undervalued, with analyst price targets ranging from $9 to $30.
The transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. This sale was not a discretionary trade by Ferguson, as it was conducted under a durable automatic sales instruction letter. Following the transaction, Ferguson holds 157,914 shares in the company. For deeper insights into insider trading patterns and comprehensive analysis, access the full Voyager Therapeutics research report on InvestingPro, covering 1,400+ US stocks.
In other recent news, Voyager Therapeutics has unveiled promising preclinical data on its Alzheimer’s therapies, VY1706 and VY7523, at the International Conference on Alzheimer’s and Parkinson’s Diseases. The data revealed that VY1706 significantly reduced tau mRNA and protein levels in non-human primates, with effects lasting up to three months. Voyager is planning to file an Investigational New Drug application for VY1706 with the FDA in 2026. Meanwhile, VY7523 showed promising results in murine studies by targeting pathologic tau tangles, with further data expected in 2026. Analysts have been active in adjusting their perspectives on Voyager Therapeutics. Canaccord Genuity maintained a Buy rating but reduced the price target to $12.00, while H.C. Wainwright reaffirmed a $30.00 target. Truist Securities also maintained their Buy rating with an $18.00 target, and Citi adjusted their target to $11.00 but upheld a Buy rating. Voyager’s financial health appears strong, with sufficient capital to continue operations into mid-2027, and potential milestone payments from partnerships with companies like Neurocrine (NASDAQ:NBIX) Biosciences and Novartis (SIX:NOVN).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.